Abstract
Proteins that inhibit the growth and aggregation of calcium oxalate crystals play important roles in the prevention of kidney stone disease. One such protein is osteopontin (OPN), which inhibits the formation of calcium oxalate monohydrate (COM) in a phosphorylation-dependent manner. To determine the role of phosphate groups in the inhibition of COM growth by OPN, we used scanning confocal interference microscopy to compare the effects of highly phosphorylated OPN from cow milk, less phosphorylated OPN from rat bone, and nonphosphorylated recombinant OPN. COM growth was measured in the principal crystallographic directions <001>, <010>, and <100>, representing lattice-ion addition to {121}, {010}, and {100} faces, respectively. While the shapes of growth curves were very consistent from crystal to crystal, absolute growth rates varied widely. To control for this, results were expressed as changes in the aspect ratios <010>/<001> and <100>/<001>. Compared to control, bone OPN increased <010>/<001> and had no effect on <100>/<001>; milk OPN had no effect on <010>/<001>and decreased <100>/<001>; recombinant OPN had no significant effect on either aspect ratio. These findings indicate that milk OPN interacts with COM crystal faces in order of preference {100} > {121} ≈ {010}, whereas bone OPN interacts in order of preference {100}≈{121} > {010}. As {100} is the most Ca2+-rich face of COM, while {010} is the least Ca2+-rich, it appears that the OPN-mediated inhibition of COM growth occurs through a nonspecific electrostatic interaction between Ca2+ ions of the crystal and phosphate groups of the protein.
Similar content being viewed by others
Notes
The convention used for indexing the faces of COM is that of Tazzoli and Domenghetti [26].
The Miller indices used by these authors have been converted to those used in the present study.
References
Herring LC (1962) Observations on the analysis of ten thousand urinary calculi. J Urol 88:545–562
Prien EL, Prien EL Jr (1968) Composition and structure of urinary stone. Am J Med 45:654–672
Coe FL, Evan A, Worcester E (2005) Kidney stone disease. J Clin Invest 115:2598–2608
Marangella M, Bagnis C, Bruno M, Vitale C, Petrarulo M, Ramello A (2004) Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis. Urol Int 72(Suppl 1):6–10
Kumar V, Lieske JC (2006) Protein regulation of intrarenal crystallization. Curr Opin Nephrol Hypertens 15:374–380
Hunter GK, Kyle CL, Goldberg HA (1994) Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 300:723–728
Shiraga H, Min W, VanDusen WJ, Clayman MD, Miner D, Terrell CH, Sherbotie JR, Foreman JW, Przysiecki C, Nielson EG, Hoyer JR (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89:426–430
Worcester EM, Blumenthal SS, Beshensky AM, Lewand DL (1992) The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 7:1029–1036
Wesson JA, Ganne V, Beshensky AM, Kleinman JG (2005) Regulation by macromolecules of calcium oxalate crystal aggregation in stone formers. Urol Res 33:206–212
Qiu SR, Wierzbicki A, Orme CA, Cody AM, Hoyer JR, Nancollas GH, Zepeda S, De Yoreo JJ (2004) Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci USA 101:1811–1815
Wesson JA, Worcester EM, Wiessner JH, Mandel NS, Kleinman JG (1998) Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int 53:952–957
Taller A, Grohe B, Rogers K, Goldberg HA, Hunter GK (2007) Specific adsorption of osteopontin and synthetic polypeptides to calcium oxalate monohydrate crystals. Biophys J 93:1768–1777
Jiang XJ, Feng T, Chang LS, Kong XT, Wang G, Zhang ZW, Guo YL (1998) Expression of osteopontin mRNA in normal and stone-forming rat kidney. Urol Res 26:389–394
Kohri K, Nomura S, Kitamura Y, Nagata T, Yoshioka K, Iguchi M, Yamate T, Umekawa T, Suzuki Y, Sinohara H, Kurita T (1993) Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 268:15180–15184
Yasui T, Fujita K, Sasaki S, Sato M, Sugimoto M, Hirota S, Kitamura Y, Nomura S, Kohri K (1999) Expression of bone matrix proteins in urolithiasis model rats. Urol Res 27:255–261
Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman JG, Hughes J (2003) Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14:139–147
Mo L, Huang HY, Zhu XH, Shapiro E, Hasty DL, Wu XR (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66:1159–1166
Sørensen ES, Højrup P, Petersen TE (1995) Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci 4:2040–2049
Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES (2005) Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390:285–292
Hunter GK, Grohe B, Jeffrey S, O’Young J, Sørensen ES, Goldberg HA (2009) Role of phosphate groups in inhibition of calcium oxalate crystal growth by osteopontin. Cells Tissues Organs. 189(1–4):44–50
Keykhosravani M, Doherty-Kirby A, Zhang C, Brewer D, Goldberg HA, Hunter GK, Lajoie G (2005) Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry. Biochemistry 44:6990–7003
Christensen B, Petersen TE, Sorensen ES (2008) Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 411:53–61
Hoyer JR, Asplin JR, Otvos L (2001) Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 60:77–82
Wang LJ, Guan XY, Tang RK, Hoyer JR, Wierzbicki A, De Yoreo JJ, Nancollas GH (2008) Phosphorylation of osteopontin is required for inhibition of calcium oxalate crystallization. J Phys Chem B 112:9151–9157
Hincke MT, St Maurice M (2000) Phosphorylation-dependent modulation of calcium carbonate precipitation by chicken eggshell matrix proteins. In: Goldberg M, Boskey A, Robinson C (eds) Chemistry and biology of mineralized tissues. American Academy of Orthopaedic Surgeons, Rosemont, IL, pp 13–17
Tazzoli V, Domenghetti C (1980) The crystal structures of whewellite and weddellite: re-examination and comparison. Am Mineralog 65:327–334
Grohe W, Rogers K, Goldberg HA, Hunter GK (2006) Crystallization kinetics of calcium oxalate hydrates studied by scanning confocal interference microscopy. J Crystal Growth 295:148–157
Goldberg HA, Sodek J (1994) Purification of mineralized tissue-associated osteopontin. J Tissue Culture Methods 16:211–215
Sorensen ES, Petersen TE (1993) Purification and characterization of three proteins isolated from the proteose peptone fraction of bovine milk. J Dairy Res 60:189–197
Millan A (2001) Crystal growth shape of whewellite polymorphs: influence of structure distortions on crystal shape. Crystal Growth Des 1:245–254
Guo SW, Ward MD, Wesson JA (2002) Direct visualization of calcium oxalate monohydrate crystallization and dissolution with atomic force microscopy and the role of polymeric additives. Langmuir 18:4284–4291
Jung T, Sheng X, Choi CK, Kim WS, Wesson JA, Ward MD (2004) Probing crystallization of calcium oxalate monohydrate and the role of macromolecule additives with in situ atomic force microscopy. Langmuir 20:8587–8596
Addadi L, Weiner S (1985) Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. Proc Natl Acad Sci USA 82:4110–4114
Kile DE, Eberl DD, Hoch AR, Reddy MM (2000) An assessment of calcite crystal growth mechanisms based on crystal size distributions. Geochim Cosmochim Acta 64:2937–2950
Kile DE, Eberl DD (2003) On the origin of size-dependent and size-independent crystal growth: influence of advection and diffusion. Am Mineralog 88:1514–1521
McCabe WL (1929) Crystal growth in aqueous solutions. Ind Eng Chem 21:30–33
Tomazic B, Nancollas GH (1979) Kinetics of dissolution of calcium-oxalate hydrates. J Crystal Growth 46:355–361
Zauner R, Jones AG (2000) Determination of nucleation, growth, agglomeration and disruption kinetics from experimental precipitation data: the calcium oxalate system. Chem Eng Sci 55:4219–4232
Sheng X, Jung T, Wesson JA, Ward MD (2005) Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. Proc Natl Acad Sci USA 102:267–272
Qiu SR, Wierzbicki A, Salter EA, Zepeda S, Orme CA, Hoyer JR, Nancollas GH, Cody AM, De Yoreo JJ (2005) Modulation of calcium oxalate monohydrate crystallization by citrate through selective binding to atomic steps. J Am Chem Soc 127:9036–9044
Boskey AL, Maresca M, Ullrich W, Doty SB, Butler WT, Prince CW (1993) Osteopontin–hydroxyapatite interactions in vitro. Inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner 22:147–159
Jono S, Peinado C, Giachelli CM (2000) Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 275:20197–20203
Pampena DA, Robertson KA, Litvinova O, Lajoie G, Goldberg HA, Hunter GK (2004) Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem J 378:1083–1087
Grohe B, O’Young J, Ionescu DA, Lajoie G, Rogers KA, Karttunen M, Goldberg HA, Hunter GK (2007) Control of calcium oxalate crystal growth by face-specific adsorption of an osteopontin phosphopeptide. J Am Chem Soc 129(48):14946–14951
Hauschka PV, Wians FH Jr (1989) Osteocalcin–hydroxyapatite interaction in the extracellular organic matrix of bone. Anat Rec 224:180–188
Huq NL, Cross KJ, Reynolds EC (2000) Molecular modelling of a multiphosphorylated sequence motif bound to hydroxyapatite surfaces. J Mol Model 6:35–47
Wen D, Laursen RA (1992) A model for binding of an antifreeze polypeptide to ice. Biophys J 63:1659–1662
Furedi-Milhofer H, Moradian-Oldak J, Weiner S, Veis A, Mintz KP, Addadi L (1994) Interactions of matrix proteins from mineralized tissues with octacalcium phosphate. Connect Tissue Res 30:251–264
Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS (2001) Flexible structures of SIBLING proteins, bone sialoprotein and osteopontin. Biochem Biophys Res Commun 280:460–465
Gericke A, Qin C, Spevak L, Fujimoto Y, Butler WT, Sorensen ES, Boskey AL (2005) Importance of phosphorylation for osteopontin regulation of biomineralization. Calcif Tissue Int 77:45–54
Acknowledgement
The skilled technical assistance of Kari Ann Orlay and Honghong Chen is gratefully acknowledged. The images shown in Fig. 5 were generated by Jason O’Young. This study was supported by the Canadian Institutes of Health Research. A. L. was the recipient of a Studentship in Musculoskeletal Research from the Institute of Musculoskeletal Health and Arthritis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Langdon, A., Wignall, G.R., Rogers, K. et al. Kinetics of Calcium Oxalate Crystal Growth in the Presence of Osteopontin Isoforms: An Analysis by Scanning Confocal Interference Microcopy. Calcif Tissue Int 84, 240–248 (2009). https://doi.org/10.1007/s00223-008-9215-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-008-9215-5